Aug 1 (Reuters) - Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, said on Friday it will remove an additional 25 products from its list of preferred drugs in 2015, including anemia drugs Epogen and Aranesp, sold by Amgen Inc.
But it will still cover Procrit, a similar anemia drug sold by Johnson & Johnson, on the list, known as a formulary.
“The products we have chosen to exclude from our formulary are those that cost significantly more than other available options but that fail to provide additional health benefit,” the company said in an emailed statement.
Help employers find you! Check out all the jobs and post your resume.
